Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2010-2-22
pubmed:abstractText
Clinical, postmortem and preclinical research strongly implicates dysregulation of glutamatergic neurotransmission in major depressive disorder (MDD). Recently, metabotropic glutamate receptors (mGluRs) have been proposed as attractive targets for the discovery of novel therapeutic approaches against depression. The aim of this study was to examine mGluR2/3 protein levels in the prefrontal cortex (PFC) from depressed subjects. In addition, to test whether antidepressants influence mGluR2/3 expression we also studied levels of mGluR2/3 in fluoxetine-treated monkeys. Postmortem human prefrontal samples containing Brodmann's area 10 (BA10) were obtained from 11 depressed and 11 psychiatrically healthy controls. Male rhesus monkeys were treated chronically with fluoxetine (dose escalated to 3mg/kg, p.o.; n=7) or placebo (n=6) for 39 weeks. The mGluR2/3 immunoreactivity was investigated using Western blot method. There was a robust (+67%) increase in the expression of the mGlu2/3 protein in the PFC of depressed subjects relative to healthy controls. The expression of mGlu2/3 was unchanged in the PFC of monkeys treated with fluoxetine. Our findings provide the first evidence that mGluR2/3 is elevated in the PFC in MDD. This observation is consistent with reports showing that mGluR2/3 antagonists exhibit antidepressant-like activity in animal models and demonstrates that these receptors are promising targets for the discovery of novel antidepressants.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-10331101, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-10686265, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-10686270, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-10936169, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-11063977, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-11840308, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-11910257, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-12063152, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-12128001, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-12786977, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-14975669, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-15237082, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-15607306, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-15823257, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-15920498, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-15945063, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-16487713, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-16612616, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-16854469, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-16894061, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-17283286, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-17430147, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-17574216, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-17582504, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-18164691, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-18425072, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-18570704, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-18590921, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-18992785, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-19211976, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-19376090, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-19481572, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-8677218, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-8684625, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-9124080, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-9131252, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-9572581, http://linkedlifedata.com/resource/pubmed/commentcorrection/19945495-9680254
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1878-4216
pubmed:author
pubmed:copyrightInfo
Copyright 2009 Elsevier Inc. All rights reserved.
pubmed:issnType
Electronic
pubmed:day
17
pubmed:volume
34
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
279-83
pubmed:dateRevised
2011-7-26
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression.
pubmed:affiliation
Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural